Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Type III immune complex mediated reaction10.01.03.023--Not Available
Nodule08.03.05.0020.000667%Not Available
Injection site discomfort12.07.03.019; 08.02.03.018--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Pulmonary mass22.02.07.0040.000667%Not Available
Colitis microscopic07.08.01.0110.000818%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000667%Not Available
Breast cancer female21.05.01.011; 16.10.01.0040.000303%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.001061%Not Available
Pseudomononucleosis10.02.01.047; 01.02.01.014--Not Available
Bicytopenia01.03.03.0100.000303%Not Available
Scleral hyperaemia06.04.07.003--Not Available
Juvenile idiopathic arthritis15.01.03.004; 10.04.06.0040.000303%Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Finger deformity15.10.03.003--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation08.01.05.007; 10.02.01.0890.000970%Not Available
Limb discomfort15.03.04.014--Not Available
Lymphoproliferative disorder16.21.02.001; 01.13.02.0010.000455%Not Available
Malnutrition14.03.02.0040.000303%Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Therapeutic reaction time decreased08.06.01.015--Not Available
Cardiac valve disease02.07.02.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Scleral disorder06.09.06.002--
Inner ear disorder04.04.02.002--Not Available
The 12th Page    First    Pre   12 13 14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene